Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing incidence of eye infections
3.2.1.2 Growing geriatric population
3.2.1.3 Increasing prevalence of contact lens wear
3.2.1.4 Increasing research and development activities
3.2.2 Industry pitfalls & challenges
3.2.2.1 Side effects associated with the antifungal medications
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 – 2032 ($ Million)
5.1 Key trends
5.2 Medical treatment
5.2.1 Drug class
5.2.1.1 Polyenes
5.2.1.1.1 Natamycin
5.2.1.1.2 Amphotericin B
5.2.1.2 Azoles
5.2.1.2.1 Triazole
5.2.1.2.1.1 Voriconazole
5.2.1.2.1.2 Fluconazole
5.2.1.2.1.3 Itraconazole
5.2.1.2.1.4 Posaconazole
5.2.1.2.2 Imidazoles
5.2.1.2.2.1 Econazole
5.2.1.2.2.2 Miconazole
5.2.1.2.2.3 Ketoconazole
5.2.1.3 Other drug classes
5.2.2 Route of administration
5.2.2.1 Topical
5.2.2.2 Oral
5.2.2.3 Injectable
5.3 Surgical treatment
Chapter 6 Market Estimates and Forecast, By Indication, 2021 – 2032 ($ Million)
6.1 Key trends
6.2 Superficial keratitis
6.3 Deep keratitis
Chapter 7 Market Estimates and Forecast, By Fungal Species, 2021 – 2032 ($ Million)
7.1 Key trends
7.2 Fusarium
7.3 Aspergillus
7.4 Candida
7.5 Cephalosporium
7.6 Other species
Chapter 8 Market Estimates and Forecast, By Age Group, 2021 – 2032 ($ Million)
8.1 Key trends
8.2 Children
8.3 Adults
8.4 Geriatric
Chapter 9 Market Estimates and Forecast, By End-User, 2021 – 2032 ($ Million)
9.1 Key trends
9.2 Hospitals
9.3 Clinics
9.4 ASCs
9.5 Other end-users
Chapter 10 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Netherlands
10.3.7 Rest of Europe
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Rest of Latin America
10.6 Middle East and Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 UAE
10.6.4 Rest of Middle East and Africa
Chapter 11 Company Profiles
11.1 Alvogen
11.2 Aurolab
11.3 Bausch Health Companies Inc.
11.4 Eyevance Pharmaceuticals LLC
11.5 Gilead Biosciences, Inc.
11.6 Glenmark Pharmaceuticals Ltd.
11.7 Leadiant Biosciences, Inc.
11.8 Merck & Co. Inc.
11.9 Novo Holdings A/S (Xellia Pharmaceuticals)
11.10 Pfizer Inc.
